Highlights of GM6 Trials where statistical significance or strong trend are achieved

https://www.facebook.com/gm604forals Normally no one expect statistical significance data from small sample size of Phase 2A trials. Most trials have a hard time even finding a positive trend. But GM6 is so potent that there are multiple statistical significance data not only in one but two neurodegenerative diseases and not in clinical data and results alone but correlated biomarkers data and results as well in both trials. Genervon Safety and Efficacy Study 1. Safety and Efficacy GM604 is a 6 amino acid endogenous,peptide. It is very safe and tolerable as shown in Phase 1 (32 subjects), ALS,Phase 2A (12 subjects), PD Phase 2A (6 subjects), Stroke (28 of 36 subjects,,not yet un-blinded). AEs and SAEs are comparable to placebo, with no reported,drug related clinically serious adverse events. 2. Trophic Effect Axon regeneration in rat with 8 mm gap,in severed sciatic nerve, p